Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Clinical Utility of Ctdna Detection By NGS for Diagnosis of CNS Lymphoma

Ana Jiménez Ubieto, Alejandro Martín-Muñoz, Ricardo Errazquin, Yanira Ruiz-Heredia, Laura Rufián, Margarita Rodríguez, Esther Parra, Tycho Baumann, Antonia Rodriguez Izquierdo, Maria Teresa Cedena Romero, Joaquin Martínez-López, Rosa Ayala, Inmaculada Rapado

Blood (2024) 144 (Supplement 1): 6227.

https://doi.org/10.1182/blood-2024-207390

Published: 2024

Journal Articles

Potential Utility of Ctdna to Detect False Positive PET/CT in the Evaluation of Lymphoma Response

Alejandro Martín-Muñoz, Ana Jiménez Ubieto, Yanira Ruiz-Heredia, Laura Rufián, Margarita Rodríguez, Tycho Baumann, Antonia Rodriguez Izquierdo, Maria Poza Santaella, Daniel Gil Alos, Pilar Sarandeses, Enrique Revilla, Gloria Figaredo, Ricardo Errazquin, Inmaculada Rapado, Rosa Ayala, Santiago Barrio, Joaquin Martínez-López

Blood (2024) 144 (Supplement 1): 6204.

https://doi.org/10.1182/blood-2024-206966

Published: 2024

Journal Articles

Intracytoplasmatic BCMA Point Mutation and Teclistamab Resistance: Genomic Assessment of a Multidrug-Resistant Multiple Myeloma Patient

Natalia Buenache Cuenda, Hipolito Nicolas Cuesta Hernández, Alicia Giménez Sánchez, Laura Carneros Blanco, Juan Manuel Rosa-Rosa, Yanira Ruiz-Heredia, Enrique Revilla, Seungbin Han, Umair Munawar, Inmaculada Rapado, Rosa Ayala, K. Martin Kortüm, Antonio Valeri, Santiago Barrio, Joaquin Martinez Lopez, Larissa Haertle

Blood (2023) 142 (Supplement 1): 1925.

https://doi.org/10.1182/blood-2023-184824

Published: 2023

Journal Articles

Parallel Monitoring of Measurable Residual Disease and Chimerism By NGS in Myelodysplastic Syndrome after Allogenic STEM Cell Transplant

Irene Zamanillo, Santiago Barrio, Alejandro Martín-Muñoz, Sara Dorado, Ana K Ballesteros, Yanira Ruiz-Heredia, Margarita Rodriguez, Carolina Martinez-Laperche, Sandra Martín, Blanca Ferrer Lores, Ivan Martin Castillo, Inmaculada Rapado, Rosa Ayala, Joaquin Martinez-Lopez, Maria Teresa Cedena Romero

Blood (2023) 142 (Supplement 1): 6781.

https://doi.org/10.1182/blood-2023-188600

Published: 2023

Journal Articles

Adoptively Infused Memory-like Natural Killer Cells Impact Adaptive Immune Responses in Patients with Acute Myeloid Leukemia

Sergio Rutella, Jayakumar Vadakekolathu, Amanda F Cashen, Nitin Mahajan, Yanira Ruiz-Heredia, Alejandro Martín-Muñoz, Santiago Barrio, Melissa M Berrien-Elliott, Jan Davidson-Moncada, Todd A Fehniger

Blood (2023) 142 (Supplement 1): 4813.

https://doi.org/10.1182/blood-2023-184986

Published: 2023

Journal Articles

Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 3514–3515.

https://doi.org/10.1182/blood-2022-166372

Published: 2022

Journal Articles

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

Blood (2021) 138 (18): 1721–1726.

https://doi.org/10.1182/blood.2020010452

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical Validation of a NGS Capture Panel to Identify Mutations, Copy Number Variations and Translocations in Patients with Multiple Myeloma

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-140711

Published: 2020

Journal Articles

Validation of the High-Risk Prognostic Score Defined By the Presence of Mutations in NRAS or TP53 in a Cohort of 497 Patients with Acute Myeloid Leukemia

Rosa Ayala, MD PhD, Pau Montesinos, MD PhD, Eva Barragán, PhD, Joaquin Martinez-Lopez, MD, Miguel A. Sanz, Yanira Ruiz-Heredia, Santiago Barrio, Juan Manuel de la Rosa, Inmaculada Rapado, Pilar Martinez, MD, Rafael Colmenares, Maria Pozas, Xabier Gutierrez, María Luz Morales, Noemí Álvarez Sánchez-Redondo

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137467

Published: 2020

Journal Articles

Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma

Joaquin Martinez Lopez, Rafael Alonso Fernández, Sandy W. Wong, MD, Rafael Rios, MD PhD, Nina Shah, MD, Maria Teresa Cedena Romero, MD PhD, Yanira Ruiz-Heredia, Jose M. Sanchez, MD, Santiago Barrio Garcia, PhD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-140352

Published: 2020

Journal Articles

Increase of Mitochondrial Activity Contributes to the Bortezomib-Relapsed in Multiple Myeloma, a Novel Therapeutic Opportunity

Alejandra Ortiz-Ruiz, BSc, Yanira Ruiz-Heredia, Mehmet Samur, PhD, Pedro Aguilar-Garrido, Maria Luz Morales, Antonio Valeri, PhD, Almudena Garcia-Ortiz, PhD, Santiago Barrio, PhD, Carmen Bárcena, Rosa Maria Garcia-Martin, Vanesa Garrido, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD, María Teresa Cedena, Joaquin Martinez-Lopez, MD PhD, Maria Linares, PhD, Miguel Gallardo, PhD

Blood (2019) 134 (Supplement_1): 4408.

https://doi.org/10.1182/blood-2019-123950

Published: 2019

Journal Articles

Focusing PI and IMiD Resistance in Multiple Myeloma: Impact of DNA Methylation

Larissa Haertle, PhD, Max Bittrich, MD, Ramya Potabattula, PhD, Matteo Claudio Da Via', MD, Umair Munawar, MS, BS, Yanira Ruiz-Heredia, Cornelia Vogt, Torsten Steinbrunn, Andoni Garitano-Trojaola, PhD, Thorsten Stuehmer, Joaquin Martinez Lopez, MD PhD, Hermann Einsele, MD, Thomas Haaf, MD PhD, K. Martin Kortüm, MD, Santiago Barrio Garcia, PhD

Blood (2018) 132 (Supplement 1): 404.

https://doi.org/10.1182/blood-2018-99-118944

Published: 2018

Journal Articles

Role of MAX As a Tumor Suppressor Driver Gene in Multiple Myeloma

Santiago Barrio Garcia, PhD, Yanira Ruiz-Heredia, Matteo Da Via', MD, Miguel Gallardo, PhD, Andoni Garitano-Trojaola, PhD, Josip Zovko, MD, Marc S Raab, MD PhD, Pieter Sonneveld, MDPhD, Esteban Braggio, PhD, A. Keith Stewart, MBChB, MBA, Hermann Einsele, Joaquín Martínez, K. Martin Kortüm, MD

Blood (2017) 130 (Supplement 1): 4347.

https://doi.org/10.1182/blood.V130.Suppl_1.4347.4347

Published: 2017

Journal Articles

5q+ MDS Patients with Low RPS14 Expression Are Candidates to Immune-Modulating Drugs

María Linares, PhD, Inmaculada Rapado, Yanira Ruiz-Heredia, Maria Teresa Cedena, Keina Quiroz, Santiago Barrio, PhD, Rosa Ayala, Joaquín Martínez

Blood (2017) 130 (Supplement 1): 5303.

https://doi.org/10.1182/blood.V130.Suppl_1.5303.5303

Published: 2017

Journal Articles

Abnormalities in Mitochondrial DNA Copy Number Have Pathogenetic and Prognostic Implications in Multiple Myeloma

Blood (2017) 130 (Supplement 1): 4378.

https://doi.org/10.1182/blood.V130.Suppl_1.4378.4378

Published: 2017

Journal Articles

IKZF1/3 and CRL4 CRBN E3 Ubiquitin Ligase Mutations Associate with IMiD Resistance in Relapsed Multiple Myeloma

Santiago Barrio Garcia, PhD, Matteo Da Via', MD, Andoni Garitano-Trojaola, PhD, Yanira Ruiz-Heredia, Max Bittrich, MD, ChangXin Shi, PhD, Yuan Zhu, Nicola Lehners, MD, Elias K Mai, MD, Marc S Raab, MD PhD, Pieter Sonneveld, MDPhD, Joaquín Martínez, Andreas Rosenwald, Esteban Braggio, PhD, Hermann Einsele, A. Keith Stewart, MBChB, MBA, K. Martin Kortüm, MD

Blood (2017) 130 (Supplement 1): 270.

https://doi.org/10.1182/blood.V130.Suppl_1.270.270

Published: 2017

Journal Articles

Targeted RNA-Seq Identify a Subset of Adolescent and Adult Patients with Acute Lymphoblastic Leukemia with BCR-ABL1-like Characteristics

Ricardo Sanchez, Mireia Morgades, M.Prob.S, Rosa Ayala, Esther Onecha, Yanira Ruiz-Heredia, Jose M. Sanchez, Susana Vives, MD, Santiago Mercadal, MD, Ramón Guardia, Marta Cervera, MD, Olga García, Jordi Ribera, Josep-Maria Ribera, MD, Joaquín Martínez

Blood (2017) 130 (Supplement 1): 2710.

https://doi.org/10.1182/blood.V130.Suppl_1.2710.2710

Published: 2017

Journal Articles

Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial

Blood (2016) 128 (22): 2078.

https://doi.org/10.1182/blood.V128.22.2078.2078

Published: 2016

Journal Articles

Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients

Beatriz Sanchez-Vega, PhD, Rafael Alonso, MD, Isabel Cuenca, Santiago Barrio, PhD, Yanira Ruiz-Heredia, Carlos Marin, Inmaculada Rapado, PhD, Cristina Jimenez, BSc, Xabier Aguirre, Rosa M. Ayala, MD PhD, Teresa Cedena, Bruno Paiva, PhD, Maria-Victoria Mateos, MD PhD, Laura Rosiñol, Joan Bladé, Jesus San Miguel, MD PhD, Ramon Garcia-Sanz, MD PhD, Juan José Lahuerta, MDPhD, Joaquín Martínez-López, MD PhD

Blood (2016) 128 (22): 3283.

https://doi.org/10.1182/blood.V128.22.3283.3283

Published: 2016

Journal Articles

Targeted Genomic Mutation Panel (M 3 P) Results from 504 Multiple Myeloma (MM) Patients

Blood (2015) 126 (23): 1795.

https://doi.org/10.1182/blood.V126.23.1795.1795

Published: 2015

NARROW

Clinical Utility of Ctdna Detection By NGS for Diagnosis of CNS Lymphoma

Potential Utility of Ctdna to Detect False Positive PET/CT in the Evaluation of Lymphoma Response

Intracytoplasmatic BCMA Point Mutation and Teclistamab Resistance: Genomic Assessment of a Multidrug-Resistant Multiple Myeloma Patient

Parallel Monitoring of Measurable Residual Disease and Chimerism By NGS in Myelodysplastic Syndrome after Allogenic STEM Cell Transplant

Adoptively Infused Memory-like Natural Killer Cells Impact Adaptive Immune Responses in Patients with Acute Myeloid Leukemia

Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

Clinical Validation of a NGS Capture Panel to Identify Mutations, Copy Number Variations and Translocations in Patients with Multiple Myeloma

Validation of the High-Risk Prognostic Score Defined By the Presence of Mutations in NRAS or TP53 in a Cohort of 497 Patients with Acute Myeloid Leukemia

Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma

Increase of Mitochondrial Activity Contributes to the Bortezomib-Relapsed in Multiple Myeloma, a Novel Therapeutic Opportunity

Focusing PI and IMiD Resistance in Multiple Myeloma: Impact of DNA Methylation

Role of MAX As a Tumor Suppressor Driver Gene in Multiple Myeloma

5q+ MDS Patients with Low RPS14 Expression Are Candidates to Immune-Modulating Drugs

Abnormalities in Mitochondrial DNA Copy Number Have Pathogenetic and Prognostic Implications in Multiple Myeloma

IKZF1/3 and CRL4 CRBN E3 Ubiquitin Ligase Mutations Associate with IMiD Resistance in Relapsed Multiple Myeloma

Targeted RNA-Seq Identify a Subset of Adolescent and Adult Patients with Acute Lymphoblastic Leukemia with BCR-ABL1-like Characteristics

Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial

Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients

Targeted Genomic Mutation Panel (M 3 P) Results from 504 Multiple Myeloma (MM) Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only